Cleerly
CEO: James Min, MD.
Current diagnostic approaches in cardiovascular disease are poor predictors of who is at high risk of having a heart attack, as 70 percent of patients are considered low risk at the time of their first heart attack.
Cleerly is a cardiology diagnostics company with a technology that provides a precise quantification and characterization of important coronary atherosclerotic features that are linked to future risk of heart attacks. It is a zero-footprint digital health solution that analyzes coronary computed tomography angiography (CCTA) scans, using an end-to-end machine-learning framework, to automatically determine atherosclerosis, stenosis, and other vital coronary findings. Cleerly’s technology can be used to improve patient diagnosis, prognosis and treatment.